Medtronic PLC $MDT Shares Acquired by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. boosted its stake in Medtronic PLC (NYSE:MDT) by 22.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 67,809 shares of the medical technology company’s stock after buying an additional 12,385 shares during the period. Geneos Wealth Management Inc.’s holdings in Medtronic were worth $5,911,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Westwood Holdings Group Inc. increased its stake in shares of Medtronic by 8.4% during the second quarter. Westwood Holdings Group Inc. now owns 134,161 shares of the medical technology company’s stock valued at $11,695,000 after acquiring an additional 10,342 shares during the period. Kestra Investment Management LLC increased its position in shares of Medtronic by 41.0% during the 2nd quarter. Kestra Investment Management LLC now owns 32,764 shares of the medical technology company’s stock valued at $2,856,000 after purchasing an additional 9,525 shares during the period. Wellington Capital Management Inc. bought a new stake in shares of Medtronic in the 2nd quarter worth $225,000. Rexford Capital Inc. acquired a new stake in shares of Medtronic in the second quarter valued at $294,000. Finally, Evergreen Capital Management LLC boosted its stake in Medtronic by 5.8% during the second quarter. Evergreen Capital Management LLC now owns 15,034 shares of the medical technology company’s stock valued at $1,321,000 after buying an additional 818 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE:MDT opened at $99.86 on Monday. The company’s fifty day moving average is $97.27 and its two-hundred day moving average is $92.96. The company has a market cap of $128.02 billion, a P/E ratio of 26.92, a price-to-earnings-growth ratio of 2.63 and a beta of 0.71. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the firm earned $1.26 earnings per share. Medtronic’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s payout ratio is presently 76.55%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on MDT shares. Argus upped their price target on shares of Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. UBS Group increased their target price on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Morgan Stanley lifted their price target on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Leerink Partners set a $120.00 price target on Medtronic and gave the company an “outperform” rating in a report on Wednesday, November 19th. Finally, Barclays increased their price objective on Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $110.44.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.